<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106180</url>
  </required_header>
  <id_info>
    <org_study_id>Sword</org_study_id>
    <nct_id>NCT04106180</nct_id>
  </id_info>
  <brief_title>SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC</brief_title>
  <official_title>An Open-label, Multicenter, Phase II Single Arm Trial of SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, multicenter, phase II single arm trial to evaluate the efficacy
      and safety of SBRT in combination with sintilimab and GM-CSF for the treatment of patients
      with advanced NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Objective Response Rate</measure>
    <time_frame>At least 6 weeks after start of treatment</time_frame>
    <description>ORR was defined as the proportion of participants with partial response (PR) or complete response (CR) to treatment as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Two years</time_frame>
    <description>Treatment-related adverse events were assessed and graded according to CTCAE v. 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in Non-irradiated Lesion</measure>
    <time_frame>At least 6 weeks after start of treatment</time_frame>
    <description>Objective Response Rate (ORR) in Non-irradiated Lesion was defined as the proportion of patients with at least 30% reduction from baseline in the longest diameter of any of non-irradiated target lesions defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at any time-point from the date of treatment initiation to the date of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Two years</time_frame>
    <description>OS was defined as the time from the date of enrollment until death by any cause. Participants still alive at the time of data analysis were censored at the date of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Two years</time_frame>
    <description>PFS was measured from the date of enrollment to the date of disease progression as defined by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 or death due to any cause, whichever occurred first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>NSCLC Stage IV</condition>
  <arm_group>
    <arm_group_label>SBRT + sintilimab + GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.</description>
    <arm_group_label>SBRT + sintilimab + GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.</description>
    <arm_group_label>SBRT + sintilimab + GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.</description>
    <arm_group_label>SBRT + sintilimab + GM-CSF</arm_group_label>
    <other_name>Stereotactic body radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18 years.

          -  ECOG PS 0-1.

          -  Pathologically confirmed stage IV NSCLC.

          -  Negative for driver genes including EGFR，ALK，and ROS-1.

          -  Patients with disease progression after first-line platinum-based therapy without
             anti-PD-1 or PD-L1 treatment.

          -  Patients with at least one lesion (size 1-5cm) eligible for SBRT (24Gy/3Fx) and
             simultaneously at least one measurable lesion (in addition to the lesion treated with
             SBRT) as defined by RECIST1.1.

          -  Patients with brain metastasis are eligible if they are asymptomatic, neurologically
             stable, and off corticosteroids.

          -  Life expectancy of more than 3 months.

          -  Patients with no indications for palliative radiotherapy in the opinion of the
             investigator.

          -  Patients with a prior history of surgery are eligible if they have recovered
             adequately from the toxicity and/or complications of surgery.

          -  Signed informed consent for the use of fresh tumor biopsies before and during the
             treatment.

          -  Women of childbearing age and men must agree to use effective contraception during the
             trial.

          -  Adequate organ function within 1 week prior to the enrollment：

               1. Adequate bone marrow function: hemoglobin ≥80g/L, white blood cell (WBC) count ≥
                  4.0 * 10 ^ 9/L or neutrophil count ≥ 1.5 * 10 ^ 9/L, and platelet count ≥ 100 *
                  10 ^ 9/L;

               2. Adequate hepatic function: total bilirubin &lt; 1.5 x upper limit of normal (ULN).
                  Note: If total bilirubin is &gt; 1.5 x ULN, direct bilirubin must ≤ ULN, Aspartate
                  aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5 ULN;

               3. Adequate renal function: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥
                  50 mL/min;

          -  Ability to understand and willingness to provide the informed consent.

        Exclusion Criteria:

          -  Prior exposure to immunomodulatory agent,including but limited to anti-PD-1 or
             anti-PD-L1 antibodies.

          -  Severe autoimmune disease: inflammatory bowel disease (including Crohn's disease and
             ulcerative colitis) 、rheumatoid arthritis、scleroderma、systemic lupus erythematosus
             、Wegener's granulomatosis and related vasculitides.

          -  Patients receiving non-platinum-based chemotherapy as first-line treatment

          -  Mixed small cell with non-small cell lung cancer histology.

          -  Pregnant or lactating women.

          -  Symptomatic interstitial lung disease or active infectious/non-infectious pneumonitis.

          -  History of any other malignancy.

          -  Patients in whom palliative radiotherapy is indicated in the opinion of the
             investigator.

          -  Active infection, congestive heart failure, myocardial infarction within the 6 months
             prior to enrollment, unstable angina pectoris or cardiac arrhythmia.

          -  Prior allergic reaction or contraindications to sintilimab and GM-CSF.

          -  Patients who have received tumor vaccine; or administration of live, attenuated
             vaccine within 4 weeks before the start of treatment. Note: Influenza vaccination is
             permitted only during influenza season, while live, attenuated influenza vaccine such
             as FluMist is not allowed.

          -  Patients receiving concurrent chemotherapy drugs,other immunosuppressive agents,or
             other investigational treatment.Long-term corticosteroid users are also excluded.

          -  Mental disorders, drug abuse, and social condition that may negatively impact
             compliance in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhengfei Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinghao Ai</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhengbo Han</last_name>
    <role>Study Director</role>
    <affiliation>Shengjing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qian Chu</last_name>
    <role>Study Director</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaorong Dong</last_name>
    <role>Study Director</role>
    <affiliation>Union Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Wu</last_name>
    <role>Study Director</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhengfei Zhu, MD</last_name>
    <phone>+86-18017312901</phone>
    <email>fuscczzf@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianjiao Ni, MD</last_name>
    <phone>13761974092</phone>
    <email>nijianjiao8@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengfei Zhu, MD</last_name>
      <phone>+86-18017312901</phone>
      <email>fuscczzf@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianjiao Ni, MD</last_name>
      <phone>13761974092</phone>
      <email>nijianjiao8@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhengfei Zhu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

